Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution

Tetsuzo Tagawa, Atsushi Osoegawa, Koji Yamazaki, Tatsuro Okamoto, Takuro Kometani, Hiroshi Wataya, Takashi Seto, Seiichi Fukuyama, Fumihiko Hirai, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: We evaluated the efficacy of the multimodality approach in treating superior sulcus non-small cell lung carcinoma (SS NSCLC). Methods: We retrospectively analyzed the records of 57 patients with SS NSCLC who were treated at our institution between 1982 and 2007. Results: During the study period, 3- and 5-year survival increased significantly from 42.6% and 42.6% in the first half of the study period (1982-1994) to 72.7% and 65.4% in the second half (1995-2007), respectively. Methods of clinical staging were unchanged between the two time periods, although the ratio of adenocarcinoma was increased, and multimodality treatment, particularly concurrent chemoradiotherapy followed by surgical resection, was used more frequently in the second half of the study period. The 5-year survival of patients who received preoperative chemoradiotherapy followed by surgery (n=27) was better than that of those who received other treatment regimen with surgery (n=22, 64.6% vs. 49.6%; P=0.044). Five-year survival in patients with complete resection after chemoradiotherapy was 70.4%. Thirteen patients (48%) achieved a pathologic complete response or minimal microscopic disease. Conclusions: Multimodality treatment with concurrent chemoradiotherapy followed by surgery appears to contribute to improved outcomes over time in patients with SS NSCLC.

Original languageEnglish
Pages (from-to)495-499
Number of pages5
JournalJournal of Surgical Oncology
Volume101
Issue number6
DOIs
Publication statusPublished - May 1 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Chemoradiotherapy
Survival
Therapeutics
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Non-small cell lung carcinoma of the superior sulcus : The evolution of treatment outcomes with multimodality treatment at a single institution. / Tagawa, Tetsuzo; Osoegawa, Atsushi; Yamazaki, Koji; Okamoto, Tatsuro; Kometani, Takuro; Wataya, Hiroshi; Seto, Takashi; Fukuyama, Seiichi; Hirai, Fumihiko; Sugio, Kenji; Ichinose, Yukito.

In: Journal of Surgical Oncology, Vol. 101, No. 6, 01.05.2010, p. 495-499.

Research output: Contribution to journalArticle

Tagawa, Tetsuzo ; Osoegawa, Atsushi ; Yamazaki, Koji ; Okamoto, Tatsuro ; Kometani, Takuro ; Wataya, Hiroshi ; Seto, Takashi ; Fukuyama, Seiichi ; Hirai, Fumihiko ; Sugio, Kenji ; Ichinose, Yukito. / Non-small cell lung carcinoma of the superior sulcus : The evolution of treatment outcomes with multimodality treatment at a single institution. In: Journal of Surgical Oncology. 2010 ; Vol. 101, No. 6. pp. 495-499.
@article{41fceb64d8c34aebb02c4bdfc570d5e9,
title = "Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution",
abstract = "Objectives: We evaluated the efficacy of the multimodality approach in treating superior sulcus non-small cell lung carcinoma (SS NSCLC). Methods: We retrospectively analyzed the records of 57 patients with SS NSCLC who were treated at our institution between 1982 and 2007. Results: During the study period, 3- and 5-year survival increased significantly from 42.6{\%} and 42.6{\%} in the first half of the study period (1982-1994) to 72.7{\%} and 65.4{\%} in the second half (1995-2007), respectively. Methods of clinical staging were unchanged between the two time periods, although the ratio of adenocarcinoma was increased, and multimodality treatment, particularly concurrent chemoradiotherapy followed by surgical resection, was used more frequently in the second half of the study period. The 5-year survival of patients who received preoperative chemoradiotherapy followed by surgery (n=27) was better than that of those who received other treatment regimen with surgery (n=22, 64.6{\%} vs. 49.6{\%}; P=0.044). Five-year survival in patients with complete resection after chemoradiotherapy was 70.4{\%}. Thirteen patients (48{\%}) achieved a pathologic complete response or minimal microscopic disease. Conclusions: Multimodality treatment with concurrent chemoradiotherapy followed by surgery appears to contribute to improved outcomes over time in patients with SS NSCLC.",
author = "Tetsuzo Tagawa and Atsushi Osoegawa and Koji Yamazaki and Tatsuro Okamoto and Takuro Kometani and Hiroshi Wataya and Takashi Seto and Seiichi Fukuyama and Fumihiko Hirai and Kenji Sugio and Yukito Ichinose",
year = "2010",
month = "5",
day = "1",
doi = "10.1002/jso.21507",
language = "English",
volume = "101",
pages = "495--499",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Non-small cell lung carcinoma of the superior sulcus

T2 - The evolution of treatment outcomes with multimodality treatment at a single institution

AU - Tagawa, Tetsuzo

AU - Osoegawa, Atsushi

AU - Yamazaki, Koji

AU - Okamoto, Tatsuro

AU - Kometani, Takuro

AU - Wataya, Hiroshi

AU - Seto, Takashi

AU - Fukuyama, Seiichi

AU - Hirai, Fumihiko

AU - Sugio, Kenji

AU - Ichinose, Yukito

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Objectives: We evaluated the efficacy of the multimodality approach in treating superior sulcus non-small cell lung carcinoma (SS NSCLC). Methods: We retrospectively analyzed the records of 57 patients with SS NSCLC who were treated at our institution between 1982 and 2007. Results: During the study period, 3- and 5-year survival increased significantly from 42.6% and 42.6% in the first half of the study period (1982-1994) to 72.7% and 65.4% in the second half (1995-2007), respectively. Methods of clinical staging were unchanged between the two time periods, although the ratio of adenocarcinoma was increased, and multimodality treatment, particularly concurrent chemoradiotherapy followed by surgical resection, was used more frequently in the second half of the study period. The 5-year survival of patients who received preoperative chemoradiotherapy followed by surgery (n=27) was better than that of those who received other treatment regimen with surgery (n=22, 64.6% vs. 49.6%; P=0.044). Five-year survival in patients with complete resection after chemoradiotherapy was 70.4%. Thirteen patients (48%) achieved a pathologic complete response or minimal microscopic disease. Conclusions: Multimodality treatment with concurrent chemoradiotherapy followed by surgery appears to contribute to improved outcomes over time in patients with SS NSCLC.

AB - Objectives: We evaluated the efficacy of the multimodality approach in treating superior sulcus non-small cell lung carcinoma (SS NSCLC). Methods: We retrospectively analyzed the records of 57 patients with SS NSCLC who were treated at our institution between 1982 and 2007. Results: During the study period, 3- and 5-year survival increased significantly from 42.6% and 42.6% in the first half of the study period (1982-1994) to 72.7% and 65.4% in the second half (1995-2007), respectively. Methods of clinical staging were unchanged between the two time periods, although the ratio of adenocarcinoma was increased, and multimodality treatment, particularly concurrent chemoradiotherapy followed by surgical resection, was used more frequently in the second half of the study period. The 5-year survival of patients who received preoperative chemoradiotherapy followed by surgery (n=27) was better than that of those who received other treatment regimen with surgery (n=22, 64.6% vs. 49.6%; P=0.044). Five-year survival in patients with complete resection after chemoradiotherapy was 70.4%. Thirteen patients (48%) achieved a pathologic complete response or minimal microscopic disease. Conclusions: Multimodality treatment with concurrent chemoradiotherapy followed by surgery appears to contribute to improved outcomes over time in patients with SS NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=77950838812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950838812&partnerID=8YFLogxK

U2 - 10.1002/jso.21507

DO - 10.1002/jso.21507

M3 - Article

C2 - 20191604

AN - SCOPUS:77950838812

VL - 101

SP - 495

EP - 499

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 6

ER -